Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

• Status: Withdrawn
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the effects of corticosteroid therapy on pulmonary fibrosis and potentially pneumothorax in patients with mild PCP (pO2 >70mmHg) combined with the standard of care treatment of antibiotic therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: George Washington University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Atovaquone; Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Dapsone; Pentamidine; Prednisone; Primaquine; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• HIV Infection,

• Hospital admission for suspected PCP,

• Confirmatory test for PCP (bronchoscopy with bronchoalveolar lavage), pO2>70 mmHg or pO2<70 mmHg while breathing room air,

• 18 years or older

Exclusion Criteria:

• Contraindications to corticosteroid therapy,

• Unable and or unwilling to perform PFTS or to return for follow-up evaluations,

• Underlying lung disease such as emphysema, untreated active tuberculosis, Uncontrolled diabetes (fasting glucose > 250 mg/dL,

• Uncontrolled hypertension (160/95 mmHg),

• Pregnancy